Centessa Pharmaceuticals-adr (CNTA)
$8.5
Performance
- $8.40$8.96$8.50
1.18%
Downside
Day's Volatility :6.2%
Upside
5.08%
- $4.34$12.45$8.50
48.94%
Downside
52 Weeks Volatility :65.14%
Upside
31.73%
Returns
| Period | Centessa Pharmaceuticals-adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -23.9% | -1.0% | 0.0% |
6 Months | 19.72% | 9.6% | 0.0% |
1 Year | 90.58% | 11.0% | 0.0% |
3 Years | -61.24% | 18.5% | -22.6% |
Highlights
Market Capitalization | 998.2M |
Book Value | $2.14 |
Earnings Per Share (EPS) | -1.42 |
Wall Street Target Price | 13.6 |
Profit Margin | 0.0% |
Operating Margin TTM | -2312.8% |
Return On Assets TTM | -27.06% |
Return On Equity TTM | -54.45% |
Revenue TTM | 6.9M |
Revenue Per Share TTM | 0.07 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -158.1M |
Diluted Eps TTM | -1.42 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.68 |
EPS Estimate Next Year | -1.83 |
EPS Estimate Current Quarter | -0.42 |
EPS Estimate Next Quarter | -0.45 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 60.0%
Technicals Summary
Sell
Neutral
Buy
Centessa Pharmaceuticals-adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Centessa Pharmaceuticals-adr | -8.11% | 19.72% | 90.58% | -61.24% | -61.24% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Centessa Pharmaceuticals-adr | NA | NA | NA | -1.68 | -0.54 | -0.27 | NA | 2.14 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Centessa Pharmaceuticals-adr | Buy | $998.2M | -61.24% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Institutional Holdings
Medicxi Ventures Management (Jersey) Ltd
17.66%General Atlantic Llc
8.56%EcoR1 Capital, LLC
4.97%Vida Ventures Advisors, LLC
3.48%Perceptive Advisors LLC
2.73%First Light Asset Management, LLC
2.66%
Company Information
centessa pharmaceuticals plc is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. the company applies an asset-centric r&d model at scale to advance a portfolio of highly validated programs led by industry leading teams. each program is developed by a centessa subsidiary and supported by a centralized infrastructure and the centessa management team. the company is headquartered in cambridge, mass.
Organization | Centessa Pharmaceuticals-adr |
Employees | 77 |
CEO | Dr. Saurabh Saha M.D., Ph.D. |
Industry | Healthcare |
